Our Resources | Association for Accessible Medicines

New White Paper - Read AAM Report on Drug Shortages

Drug Shortages in the US 2023 A Closer Look at Volume and Price Dynamics

Nov 15, 2023 | Brian Hart

AAM Statement on IQVIA Institute Report Examining Drug Shortages

Video

Nov 3, 2023 | Jennifer Soup

Join Us at Access! 2024 in Tampa, Florida

2023 The U.S. Generic & Biosimilar Medicines Savings Report

Oct 20, 2023 | AAM

Fireside Chat between FDA Commissioner Dr. Robert Califf and AAM’s Interim President and CEO, David Gaugh

Oct 18, 2023 | Jennifer Soup

GRx+Biosims 2023 Conference Recap

Biocon Biologics

Sep 13, 2023 | Jewel Smith

Member Spotlight: Biocon Biologics

2023 The U.S. Generic & Biosimilar Medicines Savings Report

Sep 6, 2023 | Monét Stanford

Generic and Biosimilar Drugs Generate $408 Billion in Savings For America’s Patients and Health-Care System in 2022

2023 The U.S. Generic & Biosimilar Medicines Savings Report

Sep 6, 2023 | Monét Stanford

Report: 2023 U.S. Generic and Biosimilar Medicines Savings Report

Semglee Launch Tracking 2023

Jul 17, 2023 | Craig Burton

Pharmacy Benefit Managers Are Blocking Patient Access to Biosimilar Insulin

Image of MN State House

Jul 5, 2023 | Susan Reilly

AAM Requests Federal Injunction to Block Minnesota’s Unconstitutional Drug Price Law

AAM - Your Generics & Biosimilars Industry

Jun 28, 2023 | Monét Stanford

U.S. Patients Rely On Generic Medicines But Increases In Drug Shortages Reflect Challenges To Their Long-Term Sustainability

AAM - Your Generics & Biosimilars Industry

Jun 22, 2023 | Erica Klinger

AAM White Paper on Shortages

supreme court

May 15, 2023 | Susan Reilly

AAM Statement on U.S. Supreme Court Decision to Decline Hearing GSK v. Teva